ATOSSA THERAPEUTICS INC. - COMMON STOCK

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

20 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

13 Jul 2023 16:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

10 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

06 Jul 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

28 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces $10M Stock Repurchase Program

27 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023

22 Jun 2023 16:15:00 By Nasdaq GlobeNewswire

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

21 Jun 2023 10:13:54 By Nasdaq GlobeNewswire

Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC

14 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

12 Jun 2023 09:15:00 By Nasdaq GlobeNewswire

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

01 Jun 2023 09:10:00 By Nasdaq GlobeNewswire